ProfileGDS5678 / 1447232_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 58% 58% 57% 58% 62% 62% 58% 58% 58% 59% 57% 60% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6433860
GSM967853U87-EV human glioblastoma xenograft - Control 23.4965958
GSM967854U87-EV human glioblastoma xenograft - Control 33.5133258
GSM967855U87-EV human glioblastoma xenograft - Control 43.3993257
GSM967856U87-EV human glioblastoma xenograft - Control 53.453658
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7554562
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.77862
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5135658
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4752758
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4763358
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5352659
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.4359357
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5943360
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5431159